← Leaderboards
Chun Li
University Of Tx Md Anderson Can Ctr
$8,657,872
Attributed
$14,783,611
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,783,611 · 9
By mechanism
R01$9,456,724 · 4
RC2$3,001,830 · 1
R44$1,000,000 · 1
U54$593,504 · 1
R21$442,002 · 1
R29$289,551 · 1
Top collaborators
- Diana S-L. Chow6 shared
- Peiying Yang5 shared
- Y. Alan Wang4 shared
- Wah Chiu3 shared
- Paolo Decuzzi3 shared
- Rebekah A. Drezek3 shared
- Mauro Ferrari3 shared
- David G. Gorenstein3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Y. Alan Wang$3,748,710
- David Fuentes$1,768,670
- Eugene J Koay$2,020,718
- Hesham M Amin$3,011,396
- Ahmed Kaseb$3,699,074
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellClinicTumorMalignant NeoplasmsDrug KineticsOrganSuccessInnovationLiverInsightTechnologyClinically RelevantNeoplasm MetastasisLaboratory MouseBiodistributionCellsFutureDoseInhibitorResistancePaclitaxelEffective TherapyQuality Of LifeResponse
Grant awards (33)
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy$627,482
R01 · FY2025 · CA · contact PI
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$577,925
R01 · FY2025 · CA · contact PI
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy$61,165
R01 · FY2025 · CA · contact PI
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy$596,109
R01 · FY2024 · CA · contact PI
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$552,266
R01 · FY2024 · CA · contact PI
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy$61,165
R01 · FY2024 · CA · contact PI
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy$614,932
R01 · FY2023 · CA · contact PI
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$569,704
R01 · FY2023 · CA · contact PI
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy$642,984
R01 · FY2022 · CA · contact PI
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$596,833
R01 · FY2022 · CA · contact PI
GS-441524 is Pharmacodynamically Equivalent to Remdesivir and Pharmacokinetically Superior Drug for the Treatment of COVID-19$442,002
R21 · FY2021 · AI · contact PI
Multifunctional Hollow Gold Nanospheres for Concurrent Photothermal-Chemotherapy$500,000
R44 · FY2016 · CA
Multifunctional Hollow Gold Nanospheres for Concurrent Photothermal-Chemotherapy$500,000
R44 · FY2015 · CA
Subcellular localization of nanoparticles$993,315
RC2 · FY2010 · GM
Subcellular localization of nanoparticles$495,098
RC2 · FY2010 · GM
Subcellular localization of nanoparticles$1,513,417
RC2 · FY2009 · GM
Near-Infrared Fluorescence Nanoparticles for Targeted Optical Imaging$580,392
R01 · FY2009 · CA · contact PI
Near-Infrared Fluorescence Nanoparticles for Targeted O*$320,000
R01 · FY2009 · CA · contact PI
Near-Infrared Fluorescence Nanoparticles for Targeted Optical Imaging$562,915
R01 · FY2008 · CA · contact PI
Near-Infrared Fluorescence Nanoparticles for Targeted Optical Imaging$562,136
R01 · FY2007 · CA · contact PI
Near-Infrared Fluorescence Nanoparticles for Targeted O*$598,263
R01 · FY2006 · CA · contact PI
Near-Infrared Fluorescence Nanoparticles for Imaging$641,000
R01 · FY2005 · CA
Assessing Angiogenesis by Near-Infrared Imaging$337,500
R01 · FY2005 · EB
Assessing Angiogenesis by Near-Infrared Imaging$337,500
R01 · FY2004 · EB
Assessing Angiogenesis by Near-Infrared Imaging$337,500
R01 · FY2003 · EB
Pilot--Novel imaging agents targeted to tumor vasculatur$296,752
U54 · FY2002 · CA
Assessing Angiogenesis by Near-Infrared Imaging$278,953
R01 · FY2002 · EB
Pilot--Novel imaging agents targeted to tumor vasculatur$296,752
U54 · FY2001 · CA
MECHANISMS OF ACTION OF HIGHLY EFFICACIOUS PGA-TAXOL$110,968
R29 · FY2001 · CA
MECHANISMS OF ACTION OF HIGHLY EFFICACIOUS PGA-TAXOL$44,646
R29 · FY2001 · CA
MECHANISMS OF ACTION OF HIGHLY EFFICACIOUS PGA-TAXOL$27,237
R29 · FY2001 · CA
Pilot--Novel imaging agents targeted to tumor vasculatur$0
U54 · FY2001 · CA
MECHANISMS OF ACTION OF HIGHLY EFFICACIOUS PGA-TAXOL$106,700
R29 · FY2000 · CA